Prospective cohort study of impulse control disorders in Parkinson's disease

Movement Disorders

Volumn 28, Issue 3, 2013, Pages 327-333

  Bastiaens, Jesse ^a   Dorfman, Benjamin J ^a   Christos, Paul J ^a   Nirenberg, Melissa J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Dopamine agonist; Dopamine agonist withdrawal syndrome; Impulse control disorder; Parkinson's disease; Prospective

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CAFFEINE; LEVODOPA; RASAGILINE; SELEGILINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DYSKINESIA; DYSTONIA; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; OUTPATIENT; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING;

ADULT; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOPAMINE AGONISTS; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS;

EID: 84875533973     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25291     Document Type: Article

References (37)

1. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-2476.
2. Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989;39(11 Suppl 2):11-19.
3. Perez-Lloret S, Rey MV, Ratti L, Rascol O. Pramipexole for the treatment of early Parkinson's disease. Expert Rev Neurother 2011;11:925-935.
4. Tsouli S, Konitsiotis S. How should we treat a patient with early Parkinson's disease?Int J Clin Pract 2010;64:1210-1219.
5. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.
6. Nirenberg MJ, Fahn S. The role of levodopa and catechol-O-methyltransferase inhibitors. In: Schapira AHV, Olanow CW, eds. Principles of Treatment in Parkinson's Disease. Philadelphia, PA:Butterworth Heinemann Elsevier;2005:3-24.
7. Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson's disease. Neurodegener Dis 2013;11:63-71.
8. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
9. Friedman JH. Punding on levodopa. Biol Psychiatry 1994;36:350-351.
10. Fasano A, Ricciardi L, Pettorruso M, Bentivoglio AR. Management of punding in Parkinson's disease: an open-label prospective study. J Neurol 2011;258:656-660.
11. Spencer AH, Rickards H, Fasano A, Cavanna AE. The prevalence and clinical characteristics of punding in Parkinson's disease. Mov Disord 2011;26:578-586.
12. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969-973.
13. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63.
14. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-595.
15. Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008;14:28-32.
16. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524-529.
17. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007;64:212-216.
18. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol 2011;69:986-996.
19. Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006;67:1258-1261.
20. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010;68:400-404.
21. Walsh RA, Lang AE. Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Mov Disord 2012;27:326-327.
22. Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010;68:963-968.
23. Khadem NR, Nirenberg MJ. Carbidopa/levodopa pharmacy errors in Parkinson's disease. Mov Disord 2010;25:2867-2871.
24. Liu AA, Boxhorn CE, Klufas MA, et al. Clinical predictors of frequent patient telephone calls in Parkinson's disease. Parkinsonism Relat Disord 2011;17:95-99.
25. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
26. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
27. Goldstein RZ, Craig AD, Bechara A, et al. The neurocircuitry of impaired insight in drug addiction. Trends Cogn Sci 2009;13:372-380.
28. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?Lancet Neurol 2003;2:595-604.
29. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993;18:247-291.
30. Limotai N, Oyama G, Go C, et al. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience. Int J Neurosci 2012;122:145-153.
31. Tanner CM. Advances in environmental epidemiology. Mov Disord 2010;25(Suppl 1):S58-S62.
32. Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:317-321.
33. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Baler R. Food and drug reward: overlapping circuits in human obesity and addiction. Curr Top Behav Neurosci 2012;11:1-24.
34. Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133:1111-1127.
35. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001;11:1136-1143.
36. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA 1997;278:125-130.
37. Kieburtz K. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord 2011;26:37-44.